PNEUMOSTEM
Biologicalhuman umbilical cord blood-derived mesenchymal stem cells
NCT Number: NCT03392467
This study is to evaluate the efficacy and safety of PNEUMOSTEM® for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia (Severe BPD) in Premature Infants. Half of subjects will receive PNEUMOSTEM, while the other half will receive a placebo.
Looking for future studies?
Notify MeUp to 13 day
All sexes
Interventional
Phase 2
Asan medical Center, Seoul, South Korea
Bronchopulmonary dysplasia (BPD) is a chronic lung disease in which premature infants and it results in significant morbidity and mortality. PNEUMOSTEM is intended to prevent and treat BPD by modulating inflammation and repairing damaged lung tissue in premature infants through paracrine effects.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
at screening and randomization
at IP administration
Exclusion criteria
human umbilical cord blood-derived mesenchymal stem cells
normal saline
Time frame: 36 weeks postmenstrual age (PMA)
Percentage of subjects who have severe BPD or are dead
Time frame: 36 weeks PMA
Percentage of subjects who have moderate/severe BPD or are dead
Time frame: prenatal 28 days/36 weeks PMA
Percentage of subjects by severity of BPD
Time frame: prenatal 28 days/36 weeks PMA and study end timepoint
Percentage of subjects in death due to lung disease
Time frame: up to 24 weeks
intubation duration
Time frame: up to 24 weeks
ventilation duration
Time frame: up to 24 weeks
continuous positive airway pressure (CPAP) treatment duration
Time frame: up to 24 weeks
treatment duration with supplemental oxygen
Time frame: up to 24 weeks
% of subjects treated with steroid for weaning ventilator
Time frame: up to 24 weeks
number of subjects with ROP with stage III or higher
Time frame: up to 24 weeks
number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy
Time frame: up to 24 weeks (visit 10)
percentile for body weight, height, and head circumference
Time frame: up to 24 weeks
days in hospitalization
Time frame: from screening to 7 days after IP administration (visit 5)
changes in tracheal suction fluid examination
Medipost Co Ltd.
Industry
A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of PNEUMOSTEM for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia in Premature Infants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02766673
Bronchopulmonary Dysplasia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07725575
Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia (BPD)
Jakarta, DKI Jakarta, Indonesia
View Trial DetailsNCT05898022
Bronchopulmonary Dysplasia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Atlanta, Georgia, United States
View Trial DetailsNCT06110481
Bronchial Diseases, Bronchial Hyperreactivity
Prague, Czechia
View Trial Details